Voyager Therapeutics (VYGR)
(Real Time Quote from BATS)
$8.56 USD
-0.24 (-2.73%)
Updated Jun 14, 2024 10:04 AM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Brokerage Reports
Voyager Therapeutics, Inc. [VYGR]
Reports for Purchase
Showing records 81 - 100 ( 145 total )
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Partnerships back VYGR Voyage in Parkinson?s and other Indications
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
$27M EV Does Little Justice to Continued Execution on the BD Front; Modest Upward Revision to Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
ABBV Collaboration Expansion Validates Vectorized Antibody Approach
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
VYGR Partners Up with NBIX for Lead PD, FA Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
The Refreshing ''Can Do'' Attitude Engendered in Mid-Cap Biotechs
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Reeling in a Big Fish Just as Focus Shifts to Maturing Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Type B Meeting Feedback Pushes Out Timelines; Near-Term Focus on Early-Stage Pipeline Execution
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Brammer Adds Another Late-Stage Program to its Growing List of Gene Therapy Clients
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
3Q18 Corporate Update; Regulatory Uncertainty Clouds Near-Term Outlook, Target Lowered to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
FDA Guidance Reversal on VY-AADC?s Registration Strategy, Decreasing PT to $18
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Pre-ASH Catalyst Calendar For Stocks Under Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
2Q18 Corporate Update-Stock in Holding Pattern; Awaiting a Trigger
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Regulatory Guidance and Posterior Administration Data as Previously Telegraphed
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Positive Posterior Trial Data and Type C Feedback Sets Stage for Pivotal Trial
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D